In a new study, a Yale Pathology team has identified a possible therapeutic target for treating obesity-induced liver cancer.
Researchers say inhibiting a molecule called fatty acid binding protein 5 (FABP5) could block tumor progression in many cases:
Inhibiting a certain protein in mice reduced obesity-induced liver tumor development, Yale researchers found. It could reveal a future treatment route.
Comments are closed.